National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities.

Neuropharmacology

NIH Clinical Research Center, Pain and Palliative Care, Bethesda, MD, USA; United States Public Health Service (USPHS), Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA. Electronic address:

Published: June 2023

The U.S. National Institutes of Health (NIH) convened a seminal first ever psychedelic drug substance-focused speaker series, from April 22 to June 10, 2021, titled the "NIH Psilocybin Research Speaker Series." This speaker series provided evidence-based scientific information to the public and the scientific community. Its aims were to assess the current state of the science, the regulatory and policy landscape, as well as to identify gaps in knowledge and understanding, ultimately serving to define future research needs. The highlights of the lectures and discussion from 26 national and international distinguished experts served as the basis for this Special Issue of Neuropharmacology. This article is part of the Special Issue on "National Institutes of Health Psilocybin Research Speaker Series".

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163373PMC
http://dx.doi.org/10.1016/j.neuropharm.2023.109467DOI Listing

Publication Analysis

Top Keywords

institutes health
12
psilocybin speaker
12
speaker series
12
national institutes
8
health psilocybin
8
state science
8
science regulatory
8
regulatory policy
8
policy landscape
8
speaker series"
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!